CareLit · DOI-Nachweis · Klinische Pädiatrie
Effect and side effects of treating chronic myeloid leukemia (CML) by imatinib in pediatric patients
DOI 10.1055/s-0030-1254453
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Eckardt, JT Tauer, BAS Jaeger, S Roettgers, N von Neuhoff, C Thiede, M Suttorp
ZeitschriftKlinische Pädiatrie
Ausgabe05/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Inhibition of the leukemia-specific bcr-abl gene rearrangement by the tyrosine kinase inhibitor (TKI) imatinib mesylate (IMA) has dramatically improved therapy of chronic myeloid leukemia (CML). Study CML-paed-II is active within the GPOH and I-BFM networks recommending IMA as frontline treatment for children since 2007. However, pediatric experience is still limited and besides bcr-abl IMA also inhibits…
Zitieren
Zitierempfehlung
L Eckardt, JT Tauer, BAS Jaeger, S Roettgers, N von Neuhoff, C Thiede, M Suttorp (2010) Effect and side effects of treating chronic myeloid leukemia (CML) by imatinib in pediatric patients. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0030-1254453
Mit CareLit weiterarbeiten